Zai Lab Price to Book Ratio 2016-2021 | ZLAB

Historical price to book ratio values for Zai Lab (ZLAB) over the last 10 years. The current price to book ratio for Zai Lab as of October 22, 2021 is 5.72.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zai Lab Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 100.75 5.71
2021-06-30 176.99 $17.64 10.03
2021-03-31 133.43 $11.41 11.70
2020-12-31 135.34 0.00
2020-03-31 51.48 0.00
2019-12-31 41.59 0.00
2019-09-30 32.35 0.00
2019-06-30 34.87 0.00
2018-12-31 23.22 0.00
2017-12-31 21.23 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.612B $0.049B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76